WE CLAIM:

1. A method for treating or preventing atrial fibrillation and/or atrial flutter in a patient in need thereof comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

2. The method of claim 1, wherein the dronedarone and ranolazine, or the salt or salts thereof are administered separately.

3. The method of claim 1, wherein the dronedarone and ranolazine or the salt or salts thereof are administered intravenously.

4. The method of claim 1, wherein the dronedarone and ranolazine or the salt or salts thereofare administered orally.

5. The method of claim 4, wherein the dronedarone and ranolazine or the salt or salts thereof are administered as a combined dosage unit.

6. The method of claim 5, wherein the combined dosage unit is a tablet.

7. The method of claim 5, wherein the amount of ranolazine or salt or salts thereof administered is from about 50 mg to about 3000 mg daily.

8. The method of claim 7, wherein the amount of ranolazine or salt or salts thereof administered is from about 50 mg to about 1500 mg daily.

9. The method of claim 4, wherein the ranolazine or salt or salts thereof is administered as a sustained release formulation.

10. The method of claim 4, wherein the amount of dronedarone or salt or salts thereof administered is from about 50 mg to about 800 mg daily.

11. The method of claim 10, wherein the amount of dronedarone or salt or salts thereof administered is from about 50 mg to about 600 mg daily.

12. The method of claim 11, wherein the amount of dronedarone or salt or salts thereof administered is from about 50 mg to about 400 mg daily.

13. The method of claim 4, wherein the dronedarone or salt or salts thereof is administered as an immediate release or sustained release formulation.

14. The method of claim 4, wherein the ranolazine or salt or salts thereof and dronedarone or salt or salts thereof are administered twice daily.

15. The method of claim 4, wherein the ranolazine or salt or salts thereof and dronedarone or salt or salts thereof are administered once daily.

16. A method for reducing undesirable side effects of dronedarone or pharmaceutically acceptable salt or salts thereof comprising coadministering a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof.

17. A method for reducing a therapeutically effective dose of dronedarone or a pharmaceutically acceptable salt or salts thereof comprising coadministering a synergistically therapeutic amount of ranolazine or salt or salts thereof.

18. A method for reducing prolongation of the QT interval in a patient caused by ranolazine or a pharmaceutically acceptable salt or salts thereof, said method comprising administering to the patient a synergistically therapeutic amount of dronedarone or pharmaceutically acceptable salt or salts thereof.

19. A method for reducing prolongation of the QT interval in a patient caused by dronedarone or a pharmaceutically acceptable salt or salts thereof, said method comprising administering to the patient a synergistically therapeutic amount of ranolazine or pharmaceutically acceptable salt or salts thereof.

20. A method for modulating ventricular and/or atrial rate in a patient in need thereof, said method comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

21. The method of claim 20, wherein AV conduction is slowed when atrial rate is high.

22. The method of claim 20, wherein atrial rate is decreased.

23. The method of claim 20, wherein heart rate is not significantly decreased during sinus rhythm.

24. A method for modulating ventricular and/or atrial rhythm in a patient in need thereof, said method comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

25. The method of claim 24, wherein sinus rhythm of the patient is maintained.

26. A method for providing rhythm and rate control of the ventricles and/or atria in a patient in need thereof, said method comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

27. The method of claim 20, 24, or 26 wherein the patient suffers from atrial fibrillation.

28. A method for reducing or preventing torsades de pointes ventricular tachycardia in a patient in need thereof, said method comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

29. A method of preventing ventricular fibrillation in patients susceptible to ventricular fibrillation, said method comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

30. A method for modulating electrical and structural remodeling in a patient in need thereof, said method comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

31. A method of treating or preventing supraventricular tachyarrhythmia or ventricular tachyarrhythmia in a patient in need thereof comprising coadministering

synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

32. A method of preventing hospitalization and/or death in a patient suffering from atrial fibrillation and/or atrial flutter comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

33. A method of preventing stroke and/or congestive heart failure in a patient in need thereof comprising coadministering synergistically therapeutic amounts of dronedarone and ranolazine or pharmaceutically acceptable salt or salts thereof.

34. A pharmaceutical formulation comprising synergistically therapeutic amounts of ranolazine and dronedarone or pharmaceutically acceptable salt or salts thereof, and a pharmaceutically acceptable carrier.

35. The pharmaceutical formulation of claim 34, formulated for intravenous administration.

36. The pharmaceutical formulation of claim 35, formulated for oral administration.

37. The pharmaceutical formulation of claim 36, wherein the formulation is in tablet form or capsule form.

38. The formulation of claim 37, wherein the tablet or capsule comprises from about 10 mg to about of 800 mg of dronedarone or a pharmaceutically acceptable salt or salts thereof.

39. The formulation of claim 38, wherein the tablet or capsule comprises from about 25 mg to about 600 mg of dronedarone or a pharmaceutically acceptable salt or salts thereof.

40. The formulation of claim 39, wherein the tablet or capsule comprises from about 25 mg to about 400 mg of dronedarone or a pharmaceutically acceptable salt or salts thereof.

41. The formulation of claim 40, wherein the tablet or capsule comprises from about 50 mg to about 200 mg of dronedarone or a pharmaceutically acceptable salt or salts thereof.

42. The formulation of claim 37, wherein the tablet or capsule comprises from about 50 mg to about 1000 mg of ranolazine or a pharmaceutically acceptable salt or salts thereof.

43. The formulation of claim 42, wherein the tablet or capsule comprises from about 100 mg to about 750 mg of ranolazine or a pharmaceutically acceptable salt or salts thereof.

44. The formulation of claim 43, wherein the tablet or capsule comprises from about 150 mg to about 375 mg of ranolazine or a pharmaceutically acceptable salt or salts thereof.

45. The formulation of claim 37, wherein the ranolazine or pharmaceutically acceptable salt or salts thereof is formulated for sustained release.

46. The formulation of claim 37, wherein the dronedarone or pharmaceutically acceptable salt or salts therof is formulated for immediate release.

47. The formulation of claim 37, wherein the dronedarone or pharmaceutically acceptable salt or salts thereof is formulated for sustained release.

WE CLAIM:

1. An invention not claimed in any divisional application.